ENHERTU Showed Statistically Significant Improvement in IDFS vs. T-DM1 in High-Risk Early Breast Cancer After Neoadjuvant ...

Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant an ...

A 55-year-old woman develops triple-negative breast cancer, rectal adenocarcinoma, and HBV reactivation during pembrolizumab ...

The DESTINY-Breast05 trial included patients with HER2-positive primary breast cancer who were at high risk of recurrence and had residual invasive disease in breast or axillary lymph nodes following ...

For patients with high-risk HER2-positive early breast cancer who have undergone neoadjuvant therapy, treatment with Enhertu ...

Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU demonstrated a highly ...

Positive topline results from a planned interim analysis of the DESTINY-Breast05 phase 3 trial showed ENHERTU demonstrated a highly statistically ...